SRPX2

Across TCGA pan-cancer cohorts, SRPX2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SRPX2 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SRPX2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SRPX2 expression acts as an unfavorable survival marker.

CCRCC, COAD, and LSCC are the cancer types where SRPX2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.399	0.932	.022	20	view →
COAD	DFS	Median	III,IV	0.838	1.000	.037	6	view →
LSCC	OS	Quartile	All	0.700	0.905	.015	5	view →
PDAC	OS	Quartile	III,IV	0.325	1.000	.040	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SRPX2–CCRCC (DFS)

Open the CCRCC breakdown →